vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $29.6M, roughly 1.3× CITIZENS FINANCIAL SERVICES INC). CITIZENS FINANCIAL SERVICES INC runs the higher net margin — 35.4% vs -3.7%, a 39.1% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 13.0%). CITIZENS FINANCIAL SERVICES INC produced more free cash flow last quarter ($35.2M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 6.9%).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

CZFS vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.3× larger
GYRE
$37.2M
$29.6M
CZFS
Growing faster (revenue YoY)
GYRE
GYRE
+20.5% gap
GYRE
33.4%
13.0%
CZFS
Higher net margin
CZFS
CZFS
39.1% more per $
CZFS
35.4%
-3.7%
GYRE
More free cash flow
CZFS
CZFS
$41.0M more FCF
CZFS
$35.2M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
6.9%
CZFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZFS
CZFS
GYRE
GYRE
Revenue
$29.6M
$37.2M
Net Profit
$10.5M
$-1.4M
Gross Margin
95.3%
Operating Margin
44.2%
0.3%
Net Margin
35.4%
-3.7%
Revenue YoY
13.0%
33.4%
Net Profit YoY
31.3%
-340.1%
EPS (diluted)
$2.17
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
GYRE
GYRE
Q4 25
$29.6M
$37.2M
Q3 25
$29.0M
$30.6M
Q2 25
$27.3M
$26.8M
Q1 25
$26.4M
$22.1M
Q4 24
$26.2M
$27.9M
Q3 24
$25.1M
$25.5M
Q2 24
$24.6M
$25.2M
Q1 24
$25.9M
$27.2M
Net Profit
CZFS
CZFS
GYRE
GYRE
Q4 25
$10.5M
$-1.4M
Q3 25
$10.0M
$5.9M
Q2 25
$8.5M
$1.6M
Q1 25
$7.6M
$3.7M
Q4 24
$8.0M
$569.0K
Q3 24
$7.5M
$2.9M
Q2 24
$5.3M
$4.5M
Q1 24
$7.0M
$9.9M
Gross Margin
CZFS
CZFS
GYRE
GYRE
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
CZFS
CZFS
GYRE
GYRE
Q4 25
44.2%
0.3%
Q3 25
42.6%
22.7%
Q2 25
38.1%
8.1%
Q1 25
35.5%
10.3%
Q4 24
37.2%
2.4%
Q3 24
36.9%
16.6%
Q2 24
25.9%
12.7%
Q1 24
32.8%
29.7%
Net Margin
CZFS
CZFS
GYRE
GYRE
Q4 25
35.4%
-3.7%
Q3 25
34.5%
19.4%
Q2 25
31.0%
5.9%
Q1 25
28.8%
16.9%
Q4 24
30.5%
2.0%
Q3 24
30.0%
11.2%
Q2 24
21.4%
18.0%
Q1 24
27.1%
36.6%
EPS (diluted)
CZFS
CZFS
GYRE
GYRE
Q4 25
$2.17
$-0.01
Q3 25
$2.09
$0.03
Q2 25
$1.76
$0.00
Q1 25
$1.60
$0.00
Q4 24
$1.64
$0.00
Q3 24
$1.57
$0.01
Q2 24
$1.10
$0.01
Q1 24
$1.48
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$34.3M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.1M
$106.0M
Total Assets
$3.1B
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
GYRE
GYRE
Q4 25
$34.3M
$52.4M
Q3 25
$31.1M
$60.0M
Q2 25
$49.5M
$54.4M
Q1 25
$36.8M
$29.9M
Q4 24
$42.2M
$26.7M
Q3 24
$36.8M
$25.1M
Q2 24
$38.4M
$25.1M
Q1 24
$29.6M
$37.4M
Stockholders' Equity
CZFS
CZFS
GYRE
GYRE
Q4 25
$338.1M
$106.0M
Q3 25
$327.7M
$101.9M
Q2 25
$313.7M
$92.0M
Q1 25
$308.3M
$68.1M
Q4 24
$299.7M
$63.3M
Q3 24
$298.7M
$63.2M
Q2 24
$286.5M
$60.4M
Q1 24
$282.7M
$56.6M
Total Assets
CZFS
CZFS
GYRE
GYRE
Q4 25
$3.1B
$166.1M
Q3 25
$3.1B
$159.4M
Q2 25
$3.0B
$152.6M
Q1 25
$3.0B
$129.8M
Q4 24
$3.0B
$125.4M
Q3 24
$3.0B
$125.2M
Q2 24
$2.9B
$120.9M
Q1 24
$2.9B
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
GYRE
GYRE
Operating Cash FlowLast quarter
$36.5M
$-5.6M
Free Cash FlowOCF − Capex
$35.2M
$-5.8M
FCF MarginFCF / Revenue
119.0%
-15.5%
Capex IntensityCapex / Revenue
4.4%
0.4%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
GYRE
GYRE
Q4 25
$36.5M
$-5.6M
Q3 25
$2.9M
$4.7M
Q2 25
$6.0M
$2.1M
Q1 25
$10.9M
$-129.0K
Q4 24
$33.2M
$-2.8M
Q3 24
$6.2M
$1.7M
Q2 24
$3.0M
$-5.5M
Q1 24
$13.5M
$2.9M
Free Cash Flow
CZFS
CZFS
GYRE
GYRE
Q4 25
$35.2M
$-5.8M
Q3 25
$2.7M
$4.0M
Q2 25
$5.5M
$1.8M
Q1 25
$10.4M
$-251.0K
Q4 24
$31.9M
$-2.8M
Q3 24
$5.6M
$1.0M
Q2 24
$2.9M
$-6.9M
Q1 24
$13.4M
$2.7M
FCF Margin
CZFS
CZFS
GYRE
GYRE
Q4 25
119.0%
-15.5%
Q3 25
9.4%
13.1%
Q2 25
20.1%
6.8%
Q1 25
39.2%
-1.1%
Q4 24
121.6%
-10.1%
Q3 24
22.3%
4.1%
Q2 24
11.8%
-27.5%
Q1 24
51.5%
9.8%
Capex Intensity
CZFS
CZFS
GYRE
GYRE
Q4 25
4.4%
0.4%
Q3 25
0.5%
2.2%
Q2 25
1.8%
1.0%
Q1 25
2.2%
0.6%
Q4 24
5.0%
0.2%
Q3 24
2.5%
2.7%
Q2 24
0.5%
5.8%
Q1 24
0.4%
0.9%
Cash Conversion
CZFS
CZFS
GYRE
GYRE
Q4 25
3.49×
Q3 25
0.29×
0.79×
Q2 25
0.71×
1.32×
Q1 25
1.44×
-0.03×
Q4 24
4.16×
-4.85×
Q3 24
0.83×
0.60×
Q2 24
0.57×
-1.21×
Q1 24
1.92×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons